- CMTA and Addex Announce CMT1A CollaborationCMTA and Addex Therapeutics Enter Collaboration to Advance GABA B PAM as Potential Treatment for CMT1A Addex Therapeutics is a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development. CMTA and Addex have formed a ...Read more ...
- Pete Foley Joins CMTA Board of DirectorsThe Charcot-Marie-Tooth Association (CMTA), the national patient advocacy organization leading CMT research, today announced the appointment of Pete Foley to its Board of Directors.Read more ...
- CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical TrialsCMTA-STAR announced $1.1 million in grants March 23 aimed at helping top CMT scientists prepare for clinical trials for CMT1X and CMT2ARead more ...
- CMTA and Pharnext Enter Biomarker Research CollaborationCollaboration focused on identifying and characterizing key biomarkers in Charcot-Marie-Tooth disease Type 1ARead more ...
- Craig Zeltsar Joins CMTA Board of DirectorsThe Charcot-Marie-Tooth Association today welcomed Craig Zeltsar, principal and co-founder of NNE Marketing, LLC, to its Board of Directors.Read more ...
Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
